Article Sidebar
Published:
Jun 2, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Cardioprotective effect of Shenxiong glucose injection on acute myocardial infarction in rats via reduction in myocardial intracellular calcium ion overload
Abstract
Purpose: To explore the cardioprotective effects and potential mechanisms of Shenxiong Glucose Injection (SGI) in rat acute myocardial infarction (AMI).
Methods: AMI model was created by ligating left anterior descending coronary artery. After 7 days’ consecutive intravenous administration of SGI, serum samples were used to conduct biochemical analysis while hearts were excised and processed for infraction size, enzyme activity, histopathology and qPCR studies. Intracellular Ca2+ {(Ca2+)i} overload in H9c2 cells was measured by laser scanning confocal microscope (LSCM).
Results: In AMI rats, pretreatment with SGI significantly ameliorated myocardial histopathologic damage. It exerted cardioprotective effect by decreasing myocardial infarct size, electrocardiogram (ECG) ST segment elevation, and CK, cTnI, BNP levels in serum. In addition, SGI significantly decreased calmodulin (CaM) and calmodulin-dependent protein kinase II (CaMK II) mRNA expression, but increased Ca2+-Mg2+-ATPase and Na+-K+-ATPase activities in myocardium. In doxorubicin (DOX)- induced H9c2 cells injury model, SGI reversed (Ca2+)i overload to protect cells.
Conclusion: The results demonstrate SGI exerts cardioprotective effect by decreasing myocardial infarct size, restoring ST segment and reversing (Ca2+)i overload. It suggests that SGI may be a new clinical candidate to treat myocardial infarction.
Keywords: Shenxiong glucose injection, Tanshinol, Ligustrazine, Myocardial infarction, Intracellular Ca2+ overload, Calmodulin, Calmodulin-dependent protein kinase II
